Modulating T cell Metabolism – From a Type I Kinase Inhibitor to an Oral Heterobifunctional Kinase Degrader

Time: 3:30 pm
day: Day Two


  • Starting from an efficacious in vitro / in vivo active type I kinase inhibitor
  • Degrading the kinase instead of blocking it has the same in vitro cellular effects on primary T cell metabolism
  • Optimizing a kinase inhibitor into an oral bifunctional degrader for in vivo use